• Cisplatin in Chemoresistance: Mechanisms, Models, and Innova

  2026-07-23

  Explore how Cisplatin (CDDP) advances cancer research through unique DNA crosslinking, apoptosis assays, and cutting-edge approaches to chemotherapy resistance. This article offers a new perspective on integrating molecular mechanisms with practical assay design.

• PARP7 Inhibition Restores IFN Signaling and Alleviates EAE i

  2026-07-23

  Xu et al. reveal that PARP7 mediates the autophagic degradation of STAT1/STAT2, suppressing type I interferon signaling and exacerbating experimental autoimmune encephalomyelitis (EAE) in mice. Pharmacological inhibition of PARP7 stabilizes STAT1/STAT2, enhances interferon responses, and relieves EAE symptoms, suggesting a new immunoregulatory target for multiple sclerosis research.

• Biotin-16-UTP: Precision RNA Labeling for Advanced Assays

  2026-07-22

  Biotin-16-UTP empowers sensitive, high-fidelity RNA labeling for detection, purification, and RNA-protein interaction studies. Its robust integration into in vitro transcription workflows advances both basic research and next-generation biosensor development.

• Iptacopan (LNP023): Applied Workflows for Complement Researc

  2026-07-22

  Iptacopan (LNP023) revolutionizes complement activation research with potent, selective inhibition of factor B, enabling precise dissection of alternative pathway mechanisms in both cellular and animal models. By integrating robust protocol parameters, troubleshooting strategies, and translational insights from the latest clinical studies, researchers can accelerate discovery and optimize outcomes in complement-mediated disease modeling.

• FerroOrange Fe²⁺ Fluorescent Probe: Advancing Live-Cell Iron

  2026-07-21

  FerroOrange, APExBIO’s Fe²⁺ fluorescent probe, sets the benchmark for real-time, live-cell intracellular iron detection. Its robust specificity, compatibility with modern imaging platforms, and proven performance in ferroptosis research empower precise, reproducible workflows even in complex models of iron metabolism.

• Carrier-Platin Nanotherapeutics: Rapid ROS-Mediated Cancer C

  2026-07-21

  Liu et al. introduce 'carrier-platin', a platinum-based nanotherapeutic that induces a rapid and non-classical cancer cell death via an intracellular ROS storm, distinct from apoptosis or ferroptosis. This innovation may overcome multidrug resistance in cancer, offering a new direction for ROS-driven chemotherapy with minimal systemic toxicity.

• Sulfo-NHS-LC-Biotin: Technical Parameters for Surface Biotin

  2026-07-20

  Sulfo-NHS-LC-Biotin enables stable, covalent biotin labeling of primary amines on cell surface proteins in aqueous conditions, addressing workflows that require selective, irreversible, extracellular modification. It is not recommended for intracellular or reversible biotinylation. Researchers should adhere to best practices for reagent handling and workflow setup to ensure consistent results.

• Fucoidan: Applied Oncology and Hepatoprotection Workflows

  2026-07-20

  Fucoidan, a sulfated α-L-Fucan, advances cancer and liver injury research with multifaceted workflows for apoptosis induction, immune modulation, and gut–liver axis protection. This guide translates the latest mechanistic breakthroughs into actionable protocols and troubleshooting strategies for reliable, reproducible results.

• Porcupine Inhibition as a Therapeutic Strategy for Scleroste

  2026-07-19

  This study demonstrates that pharmacological inhibition of porcupine (PORCN) effectively attenuates high bone mass and skeletal overgrowth in a Sost-deficient mouse model of sclerosteosis. The research establishes LGK974-mediated Wnt pathway suppression as a potential non-surgical treatment avenue, with sex-specific molecular responses and minimal impact on osteoclast function.

• Resiniferatoxin (RTX): Precision Analgesia via TRPV1 Inactiv

  2026-07-18

  Explore the science of Resiniferatoxin (RTX) as a precision analgesic targeting TRPV1 channels, with unique insights into its mechanism, dosing, and clinical promise. This article goes beyond protocols to reveal RTX's transformative impact on pain and inflammation research.

• Allosteric Biosensors Enable Native Protein Tracking in Live

  2026-07-17

  This study introduces a genetically encoded, allosteric biosensor system (circStep) for spatiotemporal visualization of endogenous protein dynamics in living cells, avoiding the artifacts of overexpression or genome editing. The platform provides a high-fidelity means to track native protein localization and abundance, with applications in drug screening and mechanistic cell biology.

• Berberrubine Modulates Vitamin K Cycle to Inhibit Thrombosis

  2026-07-17

  This study reveals that berberrubine, a principal metabolite of berberine, inhibits thrombosis in mice by targeting the vitamin K catalytic cycle, as demonstrated by integrated metabolomics and molecular docking. The findings offer mechanistic insight into safer antithrombotic drug development and highlight distinct regulatory effects compared to conventional anticoagulants.

• Proteoform-Specific Drug Interactions in Native Membrane Sys

  2026-07-16

  This study introduces a native mass spectrometry workflow allowing direct sequencing and analysis of proteoforms—including post-translationally modified and alternatively spliced forms—within intact lipid bilayers. The findings reveal that PDE5 inhibitors such as vardenafil show proteoform- and context-specific off-target binding to retinal PDE6, underscoring the importance of native environment profiling for precision drug development.

• Nicotine Signaling Drives Chronic Kidney Disease Progression

  2026-07-16

  Jain and Jaimes' review synthesizes clinical and experimental data implicating nicotine, via non-neuronal nicotinic acetylcholine receptors (nAChRs) and oxidative stress, as a mechanistic driver of chronic kidney disease (CKD) progression in smokers. These insights clarify how nicotine-induced pathways accelerate renal injury and suggest future research directions targeting oxidative and fibrotic mechanisms implicated in CKD.

• Dihydroartemisinin: Applied Workflows for Malaria and mTOR R

  2026-07-15

  Dihydroartemisinin, a potent Artemisia plant extract, excels as a malaria research chemical and mTOR signaling pathway inhibitor. This article details how to optimize experimental design, maximize reproducibility, and troubleshoot common pitfalls when working with APExBIO's high-purity dihydroartemisinin in advanced biomedical research.

15414 records 4/1028 page Previous Next 12345 下5页 Last page